Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

1.

The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease.

Roberts MH, Mapel DW, Thomson HN.

Clinicoecon Outcomes Res. 2015 Mar 26;7:173-84. doi: 10.2147/CEOR.S80424. eCollection 2015.

2.

EN3427: a novel cationic aminoindane with long-acting local anesthetic properties.

Banerjee M, Baranwal A, Saha S, Saha A, Priestley T.

Anesth Analg. 2015 Apr;120(4):941-9. doi: 10.1213/ANE.0000000000000629.

PMID:
25695675
3.

Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.

Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z, Tutrone RF.

Ther Adv Urol. 2014 Oct;6(5):181-91. doi: 10.1177/1756287214541798.

4.

Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.

Morgentaler A, McGettigan J, Xiang Q, Danoff TM, Gould EM.

Int J Impot Res. 2015 Mar-Apr;27(2):41-5. doi: 10.1038/ijir.2014.28. Epub 2014 Jul 24.

PMID:
25056809
5.

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group.

Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25.

PMID:
24974051
6.

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations.

Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay MR, Gilron I, Katz NP, Mehta C, Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay GW, Kalso E, Kerns RD, Leff R, Leong M, Petersen KL, Ravina BM, Rauschkolb C, Rice AS, Rowbotham MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White RE.

Pain. 2014 Sep;155(9):1683-95. doi: 10.1016/j.pain.2014.05.025. Epub 2014 May 24.

PMID:
24865794
7.

Modern utilization of penile prosthesis surgery: a national claim registry analysis.

Segal RL, Camper SB, Burnett AL.

Int J Impot Res. 2014 Sep-Oct;26(5):167-71. doi: 10.1038/ijir.2014.11. Epub 2014 May 15.

PMID:
24830674
8.

Case fatality and population mortality associated with anaphylaxis in the United States.

Ma L, Danoff TM, Borish L.

J Allergy Clin Immunol. 2014 Apr;133(4):1075-83. doi: 10.1016/j.jaci.2013.10.029. Epub 2013 Dec 14.

9.

Current topics in opioid therapy for pain management: addressing the problem of abuse.

Casty FE, Wieman MS, Shusterman N.

Clin Drug Investig. 2013 Jul;33(7):459-68. doi: 10.1007/s40261-013-0087-8. Review.

PMID:
23740336
10.

Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects.

Harnett MD, Shipley J, MacLean L, Schwiderski U, Sandage BW Jr.

Clin Drug Investig. 2013 Feb;33(2):133-41. doi: 10.1007/s40261-012-0039-8.

PMID:
23203138
11.

The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets.

Fiske WD, Jobes J, Xiang Q, Chang SC, Benedek IH.

J Pain. 2012 Jan;13(1):90-9. doi: 10.1016/j.jpain.2011.10.011.

PMID:
22208805
12.

Daily average consumption of 2 long-acting opioids: an interrupted time series analysis.

Puenpatom RA, Szeinbach SL, Ma L, Ben-Joseph RH, Summers KH.

Am Health Drug Benefits. 2012 Jan;5(1):52-60.

13.

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release.

Benedek IH, Jobes J, Xiang Q, Fiske WD.

Drug Des Devel Ther. 2011;5:455-63. doi: 10.2147/DDDT.S24372. Epub 2011 Nov 23.

14.

Overview: developmental toxicology: new directions.

Shuey D, Kim JH.

Birth Defects Res B Dev Reprod Toxicol. 2011 Oct;92(5):381-3. doi: 10.1002/bdrb.20312. Epub 2011 Jul 18.

PMID:
21770024
16.

A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.

Rubino M, Summers KH, Puenpatom A, Fu C, Ohsfeldt RL, Ben-Joseph RH.

J Manag Care Pharm. 2011 Jun;17(5):367-76.

17.

Economic impact of potential drug-drug interactions in opioid analgesics.

Summers KH, Puenpatom RA, Rajan N, Ben-Joseph R, Ohsfeldt R.

J Med Econ. 2011;14(4):390-6. doi: 10.3111/13696998.2011.583302. Epub 2011 May 17.

PMID:
21574905
18.

Migraine prevalence by age and sex in the United States: a life-span study.

Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB.

Cephalalgia. 2010 Sep;30(9):1065-72. doi: 10.1177/0333102409355601. Epub 2010 Mar 12.

PMID:
20713557
19.

Protein binding-dependent decreases in hERG channel blocker potency assessed by whole-cell voltage clamp in serum.

Margulis M, Sorota S, Chu I, Soares A, Priestley T, Nomeir AA.

J Cardiovasc Pharmacol. 2010 Apr;55(4):368-76. doi: 10.1097/FJC.0b013e3181d2ce39.

PMID:
20125032
20.

Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults.

Silver N, Sandage B, Sabounjian L, Schwiderski U, Shipley J, Harnett M.

J Clin Pharmacol. 2010 Feb;50(2):143-50. doi: 10.1177/0091270009345498. Epub 2009 Nov 30.

PMID:
19948948
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk